Table 4 Simulation results on the first and third days showing the percentage of patients achieving target exposures for different doses administered as 3-h extended infusion (EI) after 500-mg IV bolus prior to first dose on day 1

From: Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria